May. 1 at 11:29 AM
$IDXX Idexx Laboratories reports Q1 EPS
$2.96, consensus
$2.84
Reports Q1 revenue
$998M, consensus
$996.47M. "IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx, in our North American reference laboratories," said CEO Jay Mazelsky.
"Customers have been asking for a way to diagnose cancer earlier because cancer is a leading cause of mortality in dogs and earlier detection provides better treatment options. This diagnostic panel for early detection of canine lymphoma brings exceptional levels of performance, turnaround time, and it is priced to allow veterinarian partners to include it in commonly used screening and sick patient testing panels."
